Almac Group

almacgroup.com

Almac is a financially secure, privately owned organisation with over 4,500 employees located within the US, Europe and Asia. 600+ companies worldwide, including all the market leaders, use our services, testament itself to the quality, innovation and efficiency of our business as proven over the past 40+ years.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharma Tech

ASTRAZENECA'S CALQUENCE FAILS COVID-19 STUDY, JOINING THE LIST OF REPURPOSED MEDS THAT HAVE FALLEN SHORT

AstraZeneca | November 13, 2020

news image

Months after drugmakers launched an unprecedented COVID-19 research effort, some existing medicines have turned in promising results—but more of them have failed against the virus. And AstraZeneca’s blood cancer med Calquence just became one of them, falling short in two tests in hospitalized patients. AstraZeneca said Thursday that the medicine—already approved in mantle cell lymphoma—didn't help patients survive the virus and reduce respiratory failure any better th...

Read More

Business Insights

GLAUKOS LICENSES IVEENA’S INVESTIGATIONAL KERATOCONUS THERAPY

iVeena and Glaukos | August 25, 2022

news image

iVeena Delivery Systems Inc. a clinical stage biopharmaceutical company with developmental products in keratoconus and pediatric myopia, has entered into a strategic licensing agreement with Glaukos Corporation that grants Glaukos an exclusive global license to develop and commercialize IVMED-80, a pharmacologic treatment for keratoconus. Keratoconus, a rare corneal disorder, is the leading cause of primary full-thickness corneal transplantation in the United States. IVMED-80 is a...

Read More

OPTUM DRIVES UNITEDHEALTH’S BETTER-THAN-EXPECTED EARNINGS

MedCity News - | January 16, 2020

news image

In a year when healthcare costs continued to increase, UnitedHealth Group reported better-than-expected results at the end of 2019. The company reported earnings of $19.68 billion in 2019, up 13 percent year-over-year. UnitedHealth saw improving margins in most of its business segments, with its Optum segment reporting double-digit growth across the board. The company also managed to grow its already large presence in the Medicare Advantage market, despite several new competitors. Overall, Unite...

Read More

Pharma Tech

CAPACITY AND CITELINE CONNECT PARTNER FOR AI-POWERED CLINICAL TRIAL RECRUITMENT EXPERIENCE

Capacity | August 12, 2021

news image

Capacity, an AI-powered support automation platform, today announces its partnership with Citeline Connect, the all-in-one clinical trial recruitment platform developed by Informa Pharma Intelligence. The companies partnered to launch Moderna's clinical trial recruitment website with an AI-powered chatbot to provide a comprehensive experience for potential study participants. This partnership enables customers like Moderna to create engaging clinical trial recruitment websites...

Read More
news image

Pharma Tech

ASTRAZENECA'S CALQUENCE FAILS COVID-19 STUDY, JOINING THE LIST OF REPURPOSED MEDS THAT HAVE FALLEN SHORT

AstraZeneca | November 13, 2020

Months after drugmakers launched an unprecedented COVID-19 research effort, some existing medicines have turned in promising results—but more of them have failed against the virus. And AstraZeneca’s blood cancer med Calquence just became one of them, falling short in two tests in hospitalized patients. AstraZeneca said Thursday that the medicine—already approved in mantle cell lymphoma—didn't help patients survive the virus and reduce respiratory failure any better th...

Read More
news image

Business Insights

GLAUKOS LICENSES IVEENA’S INVESTIGATIONAL KERATOCONUS THERAPY

iVeena and Glaukos | August 25, 2022

iVeena Delivery Systems Inc. a clinical stage biopharmaceutical company with developmental products in keratoconus and pediatric myopia, has entered into a strategic licensing agreement with Glaukos Corporation that grants Glaukos an exclusive global license to develop and commercialize IVMED-80, a pharmacologic treatment for keratoconus. Keratoconus, a rare corneal disorder, is the leading cause of primary full-thickness corneal transplantation in the United States. IVMED-80 is a...

Read More
news image

OPTUM DRIVES UNITEDHEALTH’S BETTER-THAN-EXPECTED EARNINGS

MedCity News - | January 16, 2020

In a year when healthcare costs continued to increase, UnitedHealth Group reported better-than-expected results at the end of 2019. The company reported earnings of $19.68 billion in 2019, up 13 percent year-over-year. UnitedHealth saw improving margins in most of its business segments, with its Optum segment reporting double-digit growth across the board. The company also managed to grow its already large presence in the Medicare Advantage market, despite several new competitors. Overall, Unite...

Read More
news image

Pharma Tech

CAPACITY AND CITELINE CONNECT PARTNER FOR AI-POWERED CLINICAL TRIAL RECRUITMENT EXPERIENCE

Capacity | August 12, 2021

Capacity, an AI-powered support automation platform, today announces its partnership with Citeline Connect, the all-in-one clinical trial recruitment platform developed by Informa Pharma Intelligence. The companies partnered to launch Moderna's clinical trial recruitment website with an AI-powered chatbot to provide a comprehensive experience for potential study participants. This partnership enables customers like Moderna to create engaging clinical trial recruitment websites...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us